Lilly and Astellas Pick Over Sangamo’s Gene Therapy Assets as Biotech Slides Into Bankruptcy

Eli Lilly and Company (NYSE: LLY) and Astellas Pharma Inc. (OTCPK: ALPMY) are moving in to carve up key Sangamo Therapeutics, Inc. (OTCQB: SGMO) assets as the longtime genomic‑medicine player files for Chapter 11 bankruptcy protection in Delaware. The process sets up a court‑supervised auction in which other bidders can still challenge the current “stalking horse” deals from Lilly and Astellas.

 What Lilly and Astellas are buying

Under separate asset sale agreements, Eli Lilly will act as stalking horse bidder for Sangamo’s capsid and platform technologies, including:

• Its capsid delivery platform,
• Zinc finger platform,
• Modular integrase platform, and
• The prion disease program ST‑506.

Astellas will serve as stalking horse for Sangamo’s Fabry disease program, isaralgagene civaparvovec (ST‑920). Both bids are structured under Section 363 of the U.S. Bankruptcy Code, allowing Lilly and Astellas to acquire assets free and clear of prior debt and liens—unless a higher qualified bid emerges during the auction.

Notably, several assets are currently not included in either stalking horse package, including the clinical‑stage ST‑503 program for chronic neuropathic pain, the giroctocogene fitelparvovec gene therapy for hemophilia A, and Sangamo’s broader cell therapy and regulatory T‑cell platforms. Those programs remain available for other interested bidders, which could include strategics or specialist investors willing to take on late‑stage or niche pipelines at distressed prices.

 Why this matters for each company

For Sangamo Therapeutics (SGMO), the filing formalizes what had been a long deterioration in its financial position, despite a series of big‑ticket partnerships over the years. The company has secured debtor‑in‑possession financing from Northridge ATM LLC and affiliates to fund operations during the Chapter 11 process and to run the sales process, but equity holders now sit behind creditors and face substantial impairment risk.investor.

For Eli Lilly (LLY), the stalking horse deal extends a relationship that already included a major licensing agreement for Sangamo’s neurotropic AAV capsid STAC‑BBB, a pact originally framed as being worth up to roughly $1.4 billion in milestones. By locking in broader rights to capsid, zinc finger, and integrase platforms, Lilly may be able to consolidate access to enabling gene‑therapy technologies at a fraction of past headline valuations, strengthening its position in CNS and genetic disease programs.

For Astellas (ALPMY / 4503), the Fabry gene‑therapy program ST‑920 has been a strategic focus, and this deal gives it a clearer path to full control of that asset through the bankruptcy process. If the auction process closes as proposed, Astellas can continue Fabry development without the overhang of a distressed U.S. partner.

Investor lens

• The stalking horse structure means that Lilly and Astellas have defined opening bids and deal terms, but other bidders can still emerge and push prices higher or pick off unclaimed programs.barchart+2
• For LLY and ALPMY holders, the upside is access to de‑risked or partially validated platforms at distressed valuations, though integration and development risk remain.
• For SGMO equity, the Chapter 11 process and asset sales highlight the downside of capital‑intensive, platform‑heavy biotech models when funding windows close; recovery will depend heavily on sale proceeds versus liabilities, with a real possibility that common shareholders see little or no value at the end of the case.